Compounded vs Branded GLP-1: A Patient Decision Guide

Compounded semaglutide and tirzepatide cost $99 to $499 a month; brand Wegovy and Zepbound list near $1,000 to $1,350 a month before insurance. The price gap is the reason patients consider compounded. The honest answer is that they are not interchangeable products at different sticker prices — they are two regulatory categories with two different risk profiles. Branded carries Phase 3 trial data (STEP-1: −14.9% body weight on semaglutide 2.4 mg^[1]; SURMOUNT-1: −20.9% on tirzepatide 15 mg^[2]). Compounded has neither bioequivalence nor weight-outcome data. For most patients without insurance the assumption that the molecule behaves identically is defensible. For some patients it is not. This guide gives you a five-question framework, the red flags that should disqualify a pharmacy on the spot, and the scenarios where branded is the only right answer.

The cost vs FDA-approval framework

The decision starts with one number: what will you actually pay each month, and what are you giving up for the lower number? In May 2026:

• Compounded semaglutide (503A): $99–$299 monthly cash, structural floor near $199 (see our 16-month price trajectory). Not FDA-approved. No bioequivalence study against Wegovy (see the bioequivalence evidence review).
• Compounded tirzepatide (503A): $199–$499 monthly cash. Same regulatory category.
• Brand Wegovy / Ozempic: ~$1,349 list. NovoCare cash channel near $499–$699 monthly for select doses.
• Brand Zepbound / Mounjaro: ~$1,086 list. LillyDirect cash vials $349–$499 monthly for select strengths.

The branded premium buys an FDA approval letter backed by Phase 3 trial data in your indication, a manufacturer- controlled supply chain under cGMP inspection, and adverse- event reporting through FAERS. Compounded gives you none of those. It gives you an accessible price.

The FDA September 2025 enforcement on retatrutide compounding

Retatrutide is Eli Lilly's investigational triple agonist. It has no FDA approval in any indication as of May 2026; Phase 3 TRIUMPH is ongoing. A small number of overseas API suppliers and US §503A compounders began offering compounded retatrutide in late 2024.

In September 2025 the FDA issued enforcement notices. §503A requires the active ingredient to appear in an FDA-approved drug or on the FDA bulk substances list. Retatrutide meets neither, and there is no shortage carveout because there is no approved product to be in shortage. A provider offering compounded retatrutide in 2026 is a categorical disqualifier — the rest of its compounding work deserves the same skepticism.

Pharmacy compliance: §503A vs §503B, plus accreditation

Federal law splits compounding into two categories^[6]:

• §503A traditional compounding — state-licensed pharmacies filling patient-specific prescriptions. Inspected by state boards of pharmacy. Permitted to compound only ingredients in an FDA-approved drug, on the FDA bulk list, or in the USP/NF. Compounded GLP-1 telehealth is almost always §503A.
• §503B outsourcing facilities — FDA-registered, FDA-inspected, cGMP-compliant. Created after the 2012 New England Compounding Center meningitis outbreak. May compound larger batches without patient-specific prescriptions. Most §503B activity is sterile compounding for hospitals.

Above the federal floor, third-party accreditation is additive:

• PCAB (Pharmacy Compounding Accreditation Board, run by ACHC^[8]) audits compliance with USP <797> sterile^[10] and USP <795> non-sterile standards. Our PCAB explainer walks through what it does and does not verify.
• NABP Compounding Pharmacy Accreditation^[9] is the successor to the legacy VAWD/VPP marks.

None of these is required by federal law and none of them equates a compounded product to an FDA-approved one. They reduce avoidable variance — they do not close the regulatory gap.

Quality verification: documents to request

1. Certificate of Analysis (CofA) for the API lot in your shipment. A legitimate CofA names the supplier, lot, test methods (HPLC assay, water content, peptide impurities), and acceptance criteria. If the provider cannot produce one, decline the shipment.
2. Sterility test results for the finished compound per USP <71> and the relevant USP <797> beyond-use date framework^[10].
3. Named compounding pharmacy with verifiable state licensure and, ideally, current PCAB or NABP accreditation. The pharmacy name should appear on the shipping label.

Most compounded semaglutide and tirzepatide API used in US §503A pharmacies originates with FDA-registered facilities, most based in China and India. The relevant credential is the FDA establishment number on the supplier's records.

Dose equivalency: does compounded 2.4 mg work like Wegovy?

The assumption underneath compounded telehealth is that 2.4 mg of compounded semaglutide behaves clinically like 2.4 mg of Wegovy because the molecule is identical. That is mechanistically reasonable but not empirically tested — no published head-to-head trial has compared the two with weight as an endpoint. The closest reference point is the SURMOUNT-5 branded tirzepatide vs branded semaglutide head-to-head^[3], which is not a compounded vs branded comparison at all. Reasons compounded might behave differently at matched stated dose include excipient differences (Wegovy uses a phosphate-buffered phenol- preserved formulation; compounded versions typically use bacteriostatic water), concentration drift over the beyond-use window, and patient dose-math errors with a syringe draw versus a pre-filled pen (see our 12 pen-vs-vial differences).

Insurance reimbursement: branded only

Hard rule in 2026: no major US commercial insurer reimburses compounded GLP-1s. Compounded products lack an NDC code, are not on formulary, and are explicitly excluded by CVS Caremark, Express Scripts, and OptumRx policy. If there is any chance of branded coverage — an employer plan with an obesity benefit, a comorbid T2D indication, or an improving state Medicaid policy — the financial math almost always favors branded. A $25–$80 copay on Wegovy beats every cash compounded option. See our insurance and Medicaid hub for state-by-state status.

Bridge strategies during branded shortages

The 2022–2025 shortage carveout closed^[7], but localized supply gaps still happen. Options before reaching for a non-compliant compounded source: call other pharmacies (allocation differs across chains and independents); use LillyDirect or NovoCare cash channels; stay at your current dose if it is working and the next strength is unavailable — STEP-1 and SURMOUNT-1 both show meaningful loss at the pre-maintenance doses^[1][2]; or bridge with a §503A-compliant compounded product under physician supervision when no branded supply is accessible and clinical need is documented. The last option is the genuine §503A use case — not routine cash-pay shopping.

Red flags: walk away if you see these

• No named compounding pharmacy. If the telehealth company will not say which pharmacy fills your prescription, the answer is no.
• No CofA on request. Legitimate PCAB-accredited pharmacies maintain CofAs and can produce them.
• Foreign API without an FDA establishment number. The supplier should appear in the FDA Drug Establishments Current Registration database.
• Compounded retatrutide on the menu — categorical disqualifier in 2026.
• Pricing below the $99 monthly floor. A reputable §503A compounded semaglutide cannot be produced, tested, packaged, cold-chain shipped, and dispensed legitimately for $29 per month. Below-floor pricing means corners cut.
• No real physician evaluation before the first shipment. §503A requires a prescription from a prescriber who has evaluated the patient.
• Lifetime or 6-month prepaid lock-ins. Legitimate operations re-evaluate at intervals aligned with the Wegovy Section 2.1 dose-escalation framework.

The 5-question decision framework

1. What does branded actually cost you? Run the insurance check first. A copay or covered Medicaid fill ends the analysis. LillyDirect or NovoCare cash is the next tier and beats compounded on risk-adjusted basis.
2. Do you need an FDA-approved molecule? For T2D, cardiovascular disease, MASH (Wegovy August 2025 approval), or any indication where guideline care references the approved label, the answer is branded.
3. Can your compounding pharmacy be named, and is it accredited? Ask the question. If the answer is evasive, walk away. A named PCAB- or NABP-accredited §503A pharmacy is at least inside the framework.
4. Do you have insurance to lose? Some commercial plans deny future GLP-1 coverage if they identify that the patient has been self-paying for compounded versions of the same class.
5. What is your time horizon? The weight-loss benefit is durable as long as the medication continues. A 5-year horizon at $199 monthly cash is $11,940. The same horizon on branded with insurance can be $1,500 to $4,800. Coverage changes the arithmetic.

When compounded makes clinical sense

• True shortage bridge with documented need when no branded allocation is accessible.
• Financial necessity without insurance and without eligibility for manufacturer patient-assistance programs — the patient understands the regulatory trade-off and the prescriber documents the discussion.
• Documented intolerance to a branded excipient (phenol reaction is the most commonly cited), where a custom excipient-free compound is a legitimate patient-specific reason.

When branded is the only right answer

• Insurance covers it. No rational basis to take on compounded regulatory risk when a copay buys the FDA-approved version.
• Personal or family history of medullary thyroid carcinoma or MEN-2. Boxed-warning contraindication for the entire class — not a compounded vs branded question; the patient should not be on a GLP-1 at all.
• Active pancreatitis history. Section 5 labeled warning. The patient should be on the FDA-approved product so FAERS adverse-event tracking and labeling-driven monitoring apply.
• Low regulatory-risk tolerance. Patient preference for FDA-approved status is reasonable and does not need defending.
• Comorbid T2D, CVD, or other covered indication. Branded coverage for these indications is broad and the guideline-recommended formulations are the branded ones.

Magnitude context: branded trial endpoints

The numbers patients quote for Wegovy and Zepbound come from trials in which participants received the FDA-approved branded product manufactured under cGMP. Compounded versions are clinically assumed to produce equivalent results, but no published trial has measured that against weight as a primary outcome.

Bottom line

• The cost gap is real and the regulatory gap is real. They do not negotiate around each other.
• For insured patients, branded is almost always correct. Use the benefit.
• For uninsured patients, compounded at a named PCAB- or NABP-accredited §503A pharmacy with documented CofA, sterility testing, and a real clinical evaluation is defensible — not equivalent to branded, but not categorically unsafe.
• Compounded retatrutide and any unapproved-molecule compounded product are off the menu in 2026.
• Below the $99 monthly floor, pricing is signaling cut corners. The math does not support that price point legitimately.
• The 5-question framework — cost, FDA status, pharmacy partner, insurance, time horizon — resolves the decision for most patients in under 10 minutes.

Related research and tools

• Compounded semaglutide vs Wegovy: bioequivalence evidence
• Compounded tirzepatide vs Zepbound: bioequivalence
• What PCAB accreditation actually means
• Compounded GLP-1 prices over 16 months
• Wegovy pen vs compounded vial: 12 practical differences
• Compounded GLP-1 plateau decision tree
• Cheapest compounded semaglutide comparison table
• Insurance and Medicaid coverage hub

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about compounded vs branded GLP-1 therapy should be made with a licensed prescriber who has evaluated your full medical history, insurance status, and clinical context. GLP-1 receptor agonists carry a boxed warning regarding medullary thyroid carcinoma risk and are contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Patients should not self-source GLP-1 medications outside the licensed pharmacy framework. Compounded medications are not FDA-approved and have not been demonstrated to be bioequivalent to the corresponding FDA-approved products. PMIDs verified against the PubMed E-utilities API on 2026-05-28; FDA, DailyMed, PCAB, NABP, and USP references verified live the same date.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if FDA enforcement guidance changes for compounded GLP-1 receptor agonists.